【优质】冠心病抗血小板治疗现状及进展_韩雅玲.pptVIP

氯吡格雷抵抗患者合用GPI的疗效 * Key subgroup analysis showed that clinically or angiographically high-risk patients benefited more from triple antiplatelet treatment. Which indicated that angiographically high-risk factors, as well as clinical risk factors, are important for the decision-make of antiplatelet strategy. A comprehensive consideration of clinical and angiographic characteristics for each patient is helpful for the choice of dual or triple antiplatelet therapy. * * * * * * * * This figure shows the cumulative hazard for MACCE of different antipletelet regimen. The two curves separated obviousl